WeTrials

A Phase II Study of Niraparib in Patients With Advanced Melanoma With Genetic Homologous Recombination (HR) Mutation / Alteration

What is this study?

This study is testing a medication called niraparib for people with advanced skin cancer that has spread. It aims to see if this targeted drug can slow or stop tumor growth by blocking specific DNA repair processes in cancer cells with certain gene traits.

Who can participate?

You may be eligible if you have advanced melanoma with specific gene changes related to DNA repair, and your cancer has continued to grow despite prior treatments. Participants also need to be well enough to carry out light daily activities.

What will happen?

Participants in this trial will receive the study medication, niraparib, and will have their health and tumor size closely monitored with imaging scans. Doctors will check how well the treatment works and watch out for any side effects.

Where and when?

This study takes place in San Francisco, California. The current recruitment status is listed as unknown, so we recommend reaching out directly to the study team for the latest updates.

Key Points
  • 1Tests the targeted cancer drug niraparib for advanced melanoma.
  • 2Designed for patients whose cancer has specific DNA repair gene mutations.
  • 3Located in San Francisco, California.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Melanoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.